ArticleCurrent review of pain1999
Management of Inflammatory Pain with Selective COX-2 Inhibitors: Promises and Facts.
Article in Current review of pain, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 13 citations in OpenAlex.
- Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain.Journal of the American Association for Laboratory Animal Science : JAALAS · 2015Article
- Nimesulide induced histopathological changes in the vas deferens of mice.Journal of clinical and diagnostic research : JCDR · 2013Article
- Antinociception and the new COX inhibitors: research approaches and clinical perspectives.CNS drug reviews · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery that two cyclooxygenase (COX) isoenzymes, including inducible forms (COX-2), could be selectively inhibited has triggered new research to develop selective inhibitors. During this process, pharmacotherapeutic concepts in inflammatory pain, and clinicians over-expectations, have created some degree of uncertainty for clinicians about the promise of COX-2 inhibitors and the real role they play. The purpose of this article is to critically review, within the context of NSAIDs, some of the old and new concepts in the management of inflammatory pain, as well as to examine the current evidence of the usefulness of COX-2 inhibitors today.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.